No 02 2017

Elicera Therapeutics has reported continued strong results from its Phase I/IIa CARMA study of ELC-301 in relapsed or refractory B-cell lymphoma, with an overall response rate of 91 percent and disease control in all evaluable patients.

The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.

The FDA has granted Premarket Approval (PMA) for RefluxStop, the company’s implant-based treatment for gastroesophageal reflux disease (GERD).

Swedish biotech company Akiram Therapeutics has signed an agreement with ITM Isotope Technologies Munich to supply non-carrier-added lutetium-177 for the clinical development of AKIR001.

Eyedentity, a company in the Karolinska Institutet Innovation Incubator, has closed an oversubscribed investment round led by Norrsken Launcher.

Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.

Merck and Moderna have reported positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda in patients with completely resected, high-risk melanoma.